Apolipoprotein L1 is a tumor suppressor in clear cell renal cell carcinoma metastasis

• Published in: Frontiers in oncology Vol. 14; p. 1371934
• Main Authors: Le, Linh Nguy-Hoang, Choi, Cheolwon, Han, Jae-A, Kim, Eun-Bit, Trinh, Van Ngu, Kim, Yong-June, Ryu, Seongho
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2024
• Subjects: Akt; APOL1; EMT; metastasis; renal cell carcinoma; tumor suppressor; focal adhesion; renal cell carcinoma; metastasis; miRNA; tumor suppressor; Akt; APOL1; EMT
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1371934

The 5-year survival rate of kidney cancer drops dramatically from 93% to 15% when it is metastatic. Metastasis constitutes for 30% of kidney cancer cases, in which clear cell renal cell carcinoma (ccRCC) is the most prominent subtype. By sequencing mRNA of ccRCC patient samples, we found that apolipoprotein L1 (APOL1) was highly expressed in tumors compared to their adjacent normal tissues. This gene has been previously identified in a large body of kidney disease research and was reported as a potential prognosis marker in many types of cancers. However, the molecular function of APOL1 in ccRCC, especially in metastasis, remained unknown. In this study, we modulated the expression of APOL1 in various renal cancer cell lines and analyzed their proliferative, migratory, and invasive properties. Strikingly, APOL1 overexpression suppressed ccRCC metastasis both and . We then explored the mechanism by which APOL1 alleviated ccRCC malignant progression by investigating its downstream pathways. APOL1 overexpression diminished the activity of focal adhesive molecules, Akt signaling pathways, and EMT processes. Furthermore, in the upstream, we discovered that miR-30a-3p could inhibit APOL1 expression. In conclusion, our study revealed that APOL1 play a role as a tumor suppressor in ccRCC and inhibit metastasis, which may provide novel potential therapeutic approaches for ccRCC patients.